macromolecular drugs Flashcards

1
Q

what therapy can macromolecular drugs be used in

A

replacement therapy

supplementing therapy

therapeutic antibodies

site-specific carriers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the ideal route for administration of macromolecular drugs?

A

oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

list 8 examples of macromolecular drugs (peptides and protein)

8

A

Examples:

Colony stimulating factors

Interferons & Interleukins

Enzymes

Hormones

Recombinant protein vaccines

Growth factors

Monoclonal antibodies (diagnostic and therapeutic)

Recombinant soluble receptors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

list two macromolecular drug (peptides and protein) growth factors

A

Tissue/bone growth factors

Neurotropic factors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

why does monoclonal antibodies and macromolecular drugs need to be administered in high concentration?

A

because only a fraction of the administered drug will reach the site of action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are the problems with having a drug with high concentration

A

high viscosity
low solubility
aggregation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what are the barriers to manufacturing and delivery of peptide and proteins macromolecular drugs

A

in-vitro stability barriers
metabolic barriers
absorption barriers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

explain in-vitro instability barriers are a problem

A

peptides and proteins are not very stable also they can undergo enhanced instability due condition used during the manufacturing and storage of the drugs

this instability is caused by three main factors :

Inherent instability due to reactive side chains

Degradation caused by environmental factors

Manufacturing process

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

explain how Inherent instability due to reactive side chains makes the drug unstable (8)

what is done to avoid this?

why should this be avoided

A
Transpeptidation
Deamination
Side-chain hydrolysis
Proteolysis
Disulfide exchange
β-elimination
Oxidation
Racemization

eg if the drug has oxidative side chains an anti oxidant can be added to make it more stable.

it should be avoided because the reactions could lead to a loss of activity and also an exposure to hydrophobic groups which could lead to aggregation and absorption into containers (eg plastic containers).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

explain how Degradation caused by environmental factors causes drug instability

A
Temperature
 pH 
 Ionic strength 
 Pressure
 Detergents

e.g. when the temperature is increased we would have an increase in flexibility of the molecules this allows for more collision between the molecules which can lead to aggregation.

aggregation can also happen with change in pH and ionic strength because pH and ionic strength can lead to neutralization of the charges that are present in the molecules these charges have a very important role to play in solubility. neutralization would therefore cause aggregation of the molecules

detergents are often used in stabilizing and also solubilizes protein and peptides but if they are not used in the correct concentration it can lead to aggregation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

explain how manufacturing process of the drug causes drug instability

A

processes involved in manufacturing are:

Determine degradation routes

Choose adequate additives (e.g. if the drug is degraded because of oxidation an anti oxidant can be added to make it more stable)

Test stability of the solution ( when the additives required are added to the drug, the stability of the drug is tested, and if the stability of the drug is less than two years we would have to make the drug solid to give it a longer half life)

finally (development of a solid formulation)

in order to prepare solid formulation we use technics that affect peptides and protein which messes with the stability of the drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

when should a drug be made into a solid formulation?

A

when the stability after adding the adequate additives is less than two years.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what is the most commonly used technic for obtaining powder out of a solution is _______?

A

lyophilization or freeze drying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the steps in lyophilization?

A

freeze sample (in order to reduce pressure)

sublimation of water (elimination of water througgh vapour)

desorption of bound water

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are the disadvantages of lyophilization

what is done to prevent these disadvantages?

A

irreversible aggregation
denaturation

solution to disadvantage:
addition of cryoprotectants
addition of other additives

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

list different cryoprotectants

A

SUGARS
Sucrose
Sorbitol
Mannitol

POLYMERS
Dextran
PVP
PEG

OTHER
BSA (bubi serum albumin)
Amino acids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

name the second techniques used in the development of a solid formulation?

A

spray drying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

when is spray drying used?

A

this is used when we require a particular particle size.

e.g. in Nasal and pulmonary formulations

Powder with good flow properties and narrow size distribution

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

what are the steps in spray drying?

A

the solution is sprayed through a nozzle to form very tiny droplets
these droplets are then collected in a chamber where there is hot air
which induces the evaporation of water, and therefore then the collection of dry powder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

during the production of Atryn 1750 IU for solution for infusion.
what are the excipients and why are they used?

Glycine

Sodium citrate

Sodium chloride

A
Glycine as an amino acid (cryoprotectant) (additive for stabilization) 
Sodium citrate (buffer used to maintain pH and maintain the correct ionization of the solution for stability) 

Sodium chloride (used for isotonicity because once the powder is turned back into a solution, we would want an isotonic solution for injection)

21
Q

explain metabolic barriers of macromolecular drugs

A

it is basically when the drug is in the body there are enzymes which can break down its peptide bonds limiting the effectiveness of the drug.

22
Q

where are the sites of enzymatic degradation in the body and what do they do?

A

GI Lumen: pancreatic proteases (trypsin, chymotrypsin, carboxypeptidases) active against large peptides

Brush border: proteases (aminopeptidases) cleave oligopeptides (small bioactive peptides)

Intracellular degradation: most specific against dipeptides – occurs mainly in lysosomes but also occurs in other intracellular organelles

23
Q

proteins and peptides are pretty much degraded if they are taken orally true or false

A

true

24
Q

explain the absorption barrier

A

basically even if proteins and peptides are not absorbed , they would be either too big to pass through tight junctions within a cell

or they would be too hydrophilic to pass through hydrophobic cell membrane

25
Q

list each type of transport during absorption, with their problems?

A

Paracellular route - Size (absorption enhancers could help)

Passive diffusion - Size and hydrophilicity

Active transport - Size
(di- and tri-peptides)

Endocytosis - Enzymatic degradation in lysosomes

26
Q

list routes of administration in decreasing order of successful delivery

A
Parenteral
Nasal
Vaginal
Pulmonary
Rectal
Buccal 
Transdermal
Oral
27
Q

The delivery of peptides and proteins requires the use of Drug Delivery Systems able to__________

A

Protect therapeutic against metabolic barriers

Protect therapeutic against in vitro stability barriers
-Increase shelf-life of active

Ensure/promote patient compliance (i.e. avoid parenteral route)

Control release rate

  • Maintain drug levels within a desired range
  • Optimal drug use

Direct therapeutic to target site

28
Q

what are the pathways available for drug absorption

A

Transcellular pathway

b. Paracellular pathway 
Only small (MW< 100–200 Da) hydrophilic molecules; absorption limited by small surface area. 

In order to open this pathway to macromolecules, it is necessary to alter or disrupt the tight junctions that exist between cells.

c. Transcytosis and receptor-mediated endocytosis.
d. Absorption into the lymphatic circulation via M-cells of Peyer’s patches.

29
Q

explain the transcellular pathway?

A

TRANSCELLUAR route of drug absorption:

(1)Passive diffusion
small lipophilic drugs, following conc. gradient

(2)Active transport
against conc. gradient, carrier mediated

(3)Facilitated transport
follows conc. gradient, carrier mediated

(4) Receptor-mediated transport

(5) Pore transport
very small, hydrophilic drugs

(6) Pinocytosis
solid molecules, invagination of the membrane

30
Q

what are the cell junction types in the paracellular route of absorption?

A

Desmosomes (macula adherens)

Adherens Junctions (zonula adherens)

Septate Junctions

Tight Junctions (zonula occludens)

Gap Junctions

31
Q

describe tight junctions and their functions?

A

Localisation:

Epithelia lining of digestive system, ducts, cavities of glands, liver, pancreas capillary, walls urinary bladder , BBB, nasal mucosa

Functions:

1 prevent passage of molecules and ions through the space between cells, providing control over what substances are allowed through.

2 block the movement of integral membrane proteins between the surfaces of the cell maintaining their specific function: e.g. receptor-mediated endocytosis at the apical surface and exocytosis at the basolateral surface.

32
Q

When the drug is HYDROPHILIC and has a HIGH MOLECULAR WEIGHT, absorption must be favoured by using ABSORPTION ENHANCERS.

what are the Characteristic of an ideal absorption enhancer: list 6

A

Be pharmacologically inactive

Be specific in its action

Carry the intact drug to the site of absorption

Prolong its residence time at the absorbing surface

Reversibly increase the permeability of the mucosal epithelium

Do not damage the epithelium

33
Q

list 5 absorption enhancers

A

SURFACTANTS

AMINO ACID DERIVATIVES

Ca2+ CHELATORS

FATTY ACIDS

POLYMERS

34
Q

LIST 3 TYPES OF SURFACTANTS

A

non-ionic (polysorbate 80)

cationic

anionic (SDS, sodium dodecyl sulphate; bile salts)

35
Q

explain the mechanism of action of surfactant?

A

shortening of microvilli of the cells

actin disbandment

structural separation of the tight junctions

damage to the apical cell membrane by detergent-like action, the monomeric form adsorbs and penetrates the plasma membrane leading to removal of membrane constituents

36
Q

what are the experimental findings of surfactants?

A

Concentration dependent effect on permeability of Caco2 cells to hydrophilic molecules

Enhanced both paracellular and transcellular route

Anionic > non-ionic

SDS efficacy increases with MW but causes cell damage

glycosilate derivative of bile acids with increased hydrophilicity (-NH2) reduce the damage

37
Q

what is the proposed mechanism of action for amino acid derivatives as an absorption enhancer?

A

condensation with the macromolecular drug and facilitation of its absorption into the limphatic system

the condensation complex might reduce the hydrophilicity of the drug

38
Q

what is the proposed mechanism of action for Ca2+ chelators (not very active ) as an absorption enhancer?

A

disruption of actin filaments, contraction of the junction-associated microfilament cytoskeleton

disruption of adherens junctions

diminished cell adhesion

activation of protein kinases

chelation of serosal Ca2+

39
Q

explain how fatty acids work as absorption enhancers

A

Fatty acids such as sodium caprate or lauric acid can interact with the cell membrane that is lipidic in nature
C10-12 ideal lipophilic tail length

40
Q

how are polymers good as absorption enhancers?

A

Safe: not absorbed therefore no systemic side effects

Mucoadhesion: prolong contact time between drug and site of absorption

Protection from enzymatic degradation: steric hindrance

41
Q

list two polymers that work as absorption enhancers?

A

chitosan

poly(acrylic acid)

42
Q

what are the features of chitosan?

A

Biocompatible

slowly biodegradable

semi-natural polymer

only protonated chitosan is effective (pH dependent activity)

43
Q

what are the features of poly(acrylic acid)

A

Mucoadhesive

Enzyme inhibotor: chelation of Ca2+ and Zn2+ ions that are cofactors needed for the proteolitic activity of the enzymes

Absorption enhancer: facilitates the paracellular transport of macromolecules

44
Q

define mucoadhesives

A

Bioadhesives are synthetic or biological materials capable of adhering to a biological structure or tissue.

Because most biological surfaces of interest for drug administration are mucosal (covered by a mucus gel layer) in nature, the term mucoadhesion has been introduced.

Mucus is a gel-like secretion that covers all mucosal surfaces along the GIT

45
Q

what are the function of mucus

A

protection

lubrication

site specific function (i.e. buffer in stomach)

46
Q

what is MUCUS TURNOVER

A

Mucus is continually degraded
by bacterial action and replaced
by goblet cells secretion

47
Q

what is the mechanism of action mucoadhesion and relative characteristics of mucoadhesive polymers

A

wetting and swelling, the polymer comes into contact with the biological tissue 🡪 hydrophilicity

interpenetration and entanglement of polymer chains and mucin macromolecules 🡪high molecular weight and chain flexibility

formation of strong bonding between the entangled chains 🡪numerous hydrogen bond forming groups

48
Q

how do mucoadhesive promote oral drug bioavailability

A

localising the drug in a specific site

promoting intimate contact between drug and absorbing mucosa

prolonging the residence time in the GIT

protecting the drug from dilution and possible degradation